当前位置: X-MOL 学术Cell › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
First-in-class MKK4 inhibitors enhance liver regeneration and prevent liver failure
Cell ( IF 64.5 ) Pub Date : 2024-03-14 , DOI: 10.1016/j.cell.2024.02.023
Stefan Zwirner , Anan A. Abu Rmilah , Sabrina Klotz , Bent Pfaffenroth , Philip Kloevekorn , Athina A. Moschopoulou , Svenja Schuette , Mathias Haag , Roland Selig , Kewei Li , Wei Zhou , Erek Nelson , Antti Poso , Harvey Chen , Bruce Amiot , Yao Jia , Anna Minshew , Gregory Michalak , Wei Cui , Elke Rist , Thomas Longerich , Birgit Jung , Philipp Felgendreff , Omelyan Trompak , Prem K. Premsrirut , Katharina Gries , Thomas E. Muerdter , Georg Heinkele , Torsten Wuestefeld , David Shapiro , Markus Weissbach , Alfred Koenigsrainer , Bence Sipos , Eiso AB , Magdalena Ortiz Zacarias , Stephan Theisgen , Nicole Gruenheit , Saskia Biskup , Matthias Schwab , Wolfgang Albrecht , Stefan Laufer , Scott Nyberg , Lars Zender

A targeted therapy against the kinase MKK4 was developed (HRX215) and investigated preclinically, as well as in a phase I study in humans. HRX215 boosted liver regeneration, prevented liver failure after extensive hepatectomy in pigs, and holds the promise to prevent liver failure after extensive oncological liver resections or transplantation of small liver grafts in humans.

中文翻译:

一流的 MKK4 抑制剂可增强肝再生并预防肝衰竭

针对激酶 MKK4 的靶向疗法已开发出来 (HRX215),并进行了临床前研究以及人体 I 期研究。 HRX215 促进肝脏再生,预防猪广泛肝切除术后的肝衰竭,并有望预防人类广泛肿瘤性肝切除或小肝移植移植后的肝衰竭。
更新日期:2024-03-14
down
wechat
bug